Clinical-stage biopharmaceutical company SAB Biotherapeutics announced an update to the design of the ongoing Phase 3 ACTIV-2 trial evaluating the clinical efficacy and safety of SAB-185 for the treatment of participants with mild-moderate COVID infections at higher risk for progression to hospitalization.
Atara Biotherapeutics, an immunology-focused biopharmaceutical company based in San Francisco, announced a fatal serious adverse event (SAE) with a patient in a clinical trial at Memorial Sloan Kettering Cancer Center.
A multinational team of researchers genetically engineered T-lymphocytes to produce dual receptor rejuvenated T-cells, which exhibit antitumor properties with persistent, unlimited availability in vivo.
Covid-19 Vaccine Maker Clover Raises $230 Million in Series C RoundBusiness, Cancer, Clinical Trials, Coalition for Epidemic Preparedness Innovations (CEPI), COVID-19 Vaccines, Covid-19 Variants, Immunotherapy, R&D, Series C Financing, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), The Lancet
Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.
Surface Oncology agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of the Cambridge, Mass.-based biotech company’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.
FDA Action Alert: Bristol Myers Squibb/Juno, Seattle Genetics, BioMarin and TricidaAdeno-Associated Virus (AAV), B Cell Lymphomas, Biologics License Application (BLA), Brain Metastases, CAR-T Therapy, Chronic Kidney Disease, Diffuse large B-cell lymphoma (DLBCL), FDA, FDA/Regulatory, Hemophilia A, HER2-positive breast cancer, Immunotherapy, New Drug Applicationa, Project Orbis, Quarterly results, T-Cells
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell CarcinomaFDA, FDA/Regulatory, Immunotherapy, New Drug Application Submission, Renal Cell Carcinoma (RCC), Tyrosine kinase inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors
AVEO Oncology submitted a New Drug Application to the U.S. Food and Drug Administration for tivozanib, the company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, as a treatment for relapsed or refractory renal cell carcinoma (RCC).
More than 17.6 million American adults (about 7.5 percent) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
The U.S. Food and Drug Administration approved Aimmune Therapeutics’ oral immunotherapy Palforzia as a first-of-its-kind treatment for the millions of people suffering from an allergy to peanuts.
Arcus Biosciences and Roche company Genentech are partnering on two clinical trials for colorectal and pancreatic cancer.